Home / Stocks / Suraksha Diagnostic Ltd
SURAKSHA

Suraksha Diagnostic Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹329.9

Change

-18.15 (-5.21%)

Open

₹349.8

Prev. Close

₹348.05

Day High

₹349.8

Day Low

₹329.4

Volume Analysis

Traded

95,969

Delivered

56,695

Delivery %

59.08%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (33.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (60.0%)
  • •Strong 3-year revenue growth (17.7%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹363.74 ₹356.77 ₹343.34 ₹336.37 ₹322.94 ₹315.97 ₹302.54
Fibonacci ₹356.77 ₹348.98 ₹344.16 ₹336.37 ₹328.58 ₹323.76 ₹315.97
Camarilla ₹335.51 ₹333.64 ₹331.77 ₹336.37 ₹328.03 ₹326.16 ₹324.29

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+20.78%

1 Week

-3.26%

1 Month

+13.78%

3 Months

+1.26%

6 Months

+5.33%

1 Year

+9.51%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹85.85

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

13.44%

Net margin 11.85% × asset turnover 0.6x × equity multiplier 1.89x

Company Overview

Sector

Healthcare

Market Cap

₹1,780 Cr

P/E (TTM)

42.6

ROE

14.2%

Book Value

₹53.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Suraksha Diagnostic Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 67/100. The strongest factor is Growth (93/100), while Valuation (13/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (33.0%). FII holding has been falling.

TopFund Score — Fundamentals Quality

67/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

85

Growth

93

Valuation

13

Cash Flow

81

Corporate Governance

58

Momentum

74

Institutional Ownership

57

Business Quality

77

Risk & Volatility

66

Liquidity

40

From Screener.in

  • +Company has delivered good profit growth of 31.8% CAGR over last 5 years

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Audio recording of November 13, 2026 earnings call for Q2 and H1 FY27 is now available.

Investor Presentation for Quarter and Half Year ended 30 September 2026 Q2 FY 2026-27

Suraksha issued corrigendum to Q2/H1 FY27 results; corrected tests, patients and revenue metrics.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 60 52 55 61 67 60 65 73 79 78 81 88 99
Expenses + 39 36 36 40 44 41 46 49 55 55 57 57 64
Operating Profit 21 15 19 21 23 18 19 24 24 23 24 30 35
OPM % 35.0% 30.0% 35.0% 34.0% 35.0% 31.0% 29.0% 33.0% 31.0% 30.0% 30.0% 35.0% 35.0%
Other Income + 1 1 0 1 1 1 1 1 1 1 1 1 2
Interest 2 2 2 2 2 2 2 3 3 3 4 4 5
Depreciation 8 8 8 9 9 9 9 9 10 11 11 11 13
Profit before tax 11 6 9 11 14 8 9 12 12 10 10 17 19
Tax % 24.0% 27.0% 32.0% 27.0% 26.0% 26.0% 22.0% 26.0% 27.0% 28.0% 38.0% 22.0% 21.0%
Net Profit + 8 5 6 8 10 6 7 9 9 7 6 13 15
EPS in Rs 2 1 2 2 2 1 1 2 2 1 1 3 3
Raw PDF — — — — — — — — — — — — —
YoY Sales growth — — — — 11 15 18 20 18 31 25 21 26

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 158 140 223 190 219 252 310 346
Expenses + 123 115 174 143 146 170 214 233
Operating Profit 34 25 49 47 73 82 96 113
OPM % 22.0% 18.0% 22.0% 25.0% 33.0% 33.0% 31.0% 33.0%
Other Income + 2 -1 1 1 1 4 3 4
Interest 2 2 2 10 10 9 13 16
Depreciation 13 16 15 32 33 35 41 46
Profit before tax 21 6 33 7 31 41 45 55
Tax % 28.0% -1.0% 28.0% 10.0% 26.0% 25.0% 30.0% —
Net Profit + 15 6 24 6 23 31 31 41
EPS in Rs 4 1 6 2 5 6 6 8
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.0% —
Sales growth — -11 59 -15 15 15 23 25

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 111 118 141 147 171 201 234 266
Borrowings + 13 18 21 99 92 89 130 155
Other Liabilities + 42 28 32 28 30 33 73 89
Total Liabilities 173 171 201 281 300 334 448 521
Fixed Assets + 128 119 119 195 212 223 315 381
CWIP 0 0 1 2 1 11 37 17
Investments 5 5 0 0 0 1 0 0
Other Assets + 39 46 80 84 87 99 97 123
Total Assets 173 171 201 281 300 334 448 521
Equity Capital 7 7 7 7 7 10 10 10

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 31 24 42 44 60 63 82
Cash from Investing Activity + -20 -28 -44 -21 -35 -40 -52
Cash from Financing Activity + -10 3 1 -24 -25 -24 -29
Net Cash Flow 1 -1 0 -1 0 0 1
Free Cash Flow 15 8 23 32 18 21 15
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 111 100 95 109 95 90 99

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 48.78% → 49.1%
  Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 15.39% 14.71% 14.79% 15.3% 14.98% 14.31% 14.2% 15.37%
Promoters 48.78% 48.78% 48.89% 48.98% 49.0% 49.1% 49.1% 49.1%
FII 15.39% 14.46% 13.95% 13.73% 13.46% 13.46% 13.47% 13.98%
DII 20.43% 22.05% 22.37% 21.98% 22.57% 23.14% 23.22% 21.56%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Suraksha Diagnostic Ltd (this stock) 1,780 42.6 6.45 14.2%
Ngl Fine Chem Limited 1,783 27.9 4.92 17.4%
Tarsons Products Limited 1,678 205.0 2.65 2.44%
Krsnaa Diagnostics Ltd 1,661 16.9 1.6 10.9%
Syncom Formu (i) Ltd 1,907 20.0 4.06 17.6%
Fischer Medical Venture L 1,642 144.0 3.52 8.91%
Beta Drugs Limited 1,990 38.3 4.54 18.8%

Which Mutual Funds Hold Suraksha Diagnostic Ltd?

Frequently Asked Questions about Suraksha Diagnostic Ltd

Community Sentiment

What are other investors saying about Suraksha Diagnostic Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.